RxDoctor Payments Data

Annette Haynes, NP

Nurse Practitioner · Hanska, MNNPI 1891789632

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,435 of the $24,779 with a category attached, or 86.5%. Tandem Diabetes Care, Inc. accounts for 87.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $10,825 and has fallen 61.0% since, to $4,226 in 2025. Among nurse practitioner clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,779in general payments, 2019–2025

Across 93 payments — averaging $266.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$22K
  • Medtronic$3K
  • Dexcom, Inc.$460
  • Abbott$217
  • Sanofi-aventis U.S. LLC$32
  • Novo Nordisk$13

What the payments were for

  • Speaking & faculty fees$21,43587%
  • Travel & lodging$1,6587%
  • Food & beverage$1,6867%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,779 in reported general payments places this provider in the 95th percentile of 3,021 nurse practitioner providers in Minnesota.

See all nurse practitioner providers in Minnesota

Medicare billing

Part B allowed, 2024
$15,767
Medicare patients
104
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fiasp FlextouchInsulin Aspart (Niacinamide)35$26,002
OzempicSemaglutide21$19,980
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$15,629
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$12,222
Novolog FlexpenInsulin Aspart48$11,270
Levemir FlexpenInsulin Detemir23$5,057
Humalog Kwikpen U-100Insulin Lispro27$5,016
Semglee (Yfgn) PenInsulin Glargine-Yfgn12$4,698
Insulin Aspart FlexpenInsulin Aspart16$2,313
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic20$1,461
Insulin Lispro Kwikpen U-100Insulin Lispro12$1,269
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic11$1,139
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$973
Insulin Lispro13$307
Omeprazole11$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$19,98021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,021 nurse practitioner providers in Minnesota.

Other nurse practitioner in Hanska

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →